There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FKBP12


Brief Information

Name:FK506-binding protein 1A
Target Synonym:Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A,FK506-Binding Protein, T-Cell, 12-KD,FK506-Binding Protein 1A (12kD),Protein Kinase C Inhibitor 2,FK506-Binding Protein 12,FK506 Binding Protein12,FK506-Binding Protein 1,FKBP12-Exip3,Calstabin 1,PPIASE,PKC12,PKC
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FKA-H5122 Human Human FKBP12 / FKBP1A Protein, His Tag

Synonym Name



Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tacrolimus Hydrate LCP-Tacro; FR-900506; L-679934; FK-506MR; FK-506E; FK-506; MR-4; RTU-007 Approved Astellas Pharma Inc Protopic, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus, Graceptor (as hydrate), TacroBell, Advagraf, Envarsus, Modigraf, Astagraf XL, 普乐可复, Protopy United States Rejection of lung transplantation Astellas Pharma Inc 1993-01-01 Arthritis, Rheumatoid; Dermatitis, Atopic; Coronary Restenosis; Keratoconjunctivitis; Rejection in heart transplantation; Colitis, Ulcerative; Asthma; Conjunctivitis, Allergic; Psoriasis; Lupus Nephritis; Conjunctivitis; Rejection of organ transplantation; Rejection of renal transplantation; Graft vs Host Disease; Keratoplasty rejection; Glomerulonephritis, IGA; Rejection of lung transplantation; Cystitis; Renal Insufficiency; Rejection of liver transplantation; Bone marrow transplant rejection; Myasthenia Gravis; Liver Failure Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rimiducid AP-1903 Phase 2 Clinical Ariad Pharmaceuticals Inc Prostatic Neoplasms; Congenital Bone Marrow Failure Syndromes; Anemia, Sickle Cell; Lymphohistiocytosis, Hemophagocytic; Carcinoma, Pancreatic Ductal; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Urogenital Neoplasms; Metabolic Diseases; Osteopetrosis; Anemia, Aplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Uveal melanoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Fanconi Anemia; Anemia, Diamond-Blackfan; Hemoglobinopathies; Myelodysplastic Syndromes; Thalassemia; Genital Neoplasms, Male; Hematologic Neoplasms; Leukemia Details

This web search service is supported by Google Inc.